SciVision Biotech Inc.

Informe acción TWSE:1786

Capitalización de mercado: NT$7.2b

Salud financiera de hoja de balance de SciVision Biotech

Salud financiera controles de criterios 6/6

SciVision Biotech tiene un patrimonio de accionistas total de NT$1.6B y una deuda total de NT$323.8M, lo que sitúa su ratio deuda-patrimonio en 19.9%. Sus activos y pasivos totales son NT$2.2B y NT$533.7M respectivamente. El BAIT de SciVision Biotech es de NT$199.6M, por lo que su ratio de cobertura de intereses es de -29.9. Tiene efectivo e inversiones a corto plazo que ascienden a NT$745.0M.

Información clave

19.9%

Ratio deuda-patrimonio

NT$323.84m

Deuda

Ratio de cobertura de intereses-29.9x
EfectivoNT$745.00m
PatrimonioNT$1.63b
Total pasivoNT$533.67m
Activos totalesNT$2.16b

Actualizaciones recientes sobre salud financiera

Recent updates

Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Apr 01
Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Apr 20
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Apr 02
SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Mar 15
Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Feb 25
Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Feb 05
Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Jan 18
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

Jan 01
Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Dec 14
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Nov 25
Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (NT$1.0B) de 1786 superan a sus pasivos a corto plazo (NT$145.0M).

Pasivo a largo plazo: Los activos a corto plazo de 1786 (NT$1.0B) superan a sus pasivos a largo plazo (NT$388.7M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: 1786 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 1786 ha pasado de 40.3% a 19.9% en los últimos 5 años.

Cobertura de la deuda: La deuda de 1786 está bien cubierta por el flujo de caja operativo (84%).

Cobertura de intereses: 1786 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.


Hoja de balance


Descubre empresas con salud financiera